单孔胸腔镜联合肺段切除治疗磨玻璃结节的临床应用

Clinical application of uniportal thoracoscopic combined segmentectomy in the treatment of ground-glass nodules

目的:研究单孔胸腔镜联合肺段切除外科治疗磨玻璃结节的疗效和安全性。方法:回顾性分析2019年01月至2022年12月我科收治的具有手术指征的79例磨玻璃结节患者行单孔胸腔镜解剖性肺段切除作为研究对象,根据手术方式的不同分成两组,48例患者采用联合肺段切除作为观察组,31例患者采用单个肺段切除作为对照组,对比两组手术相关情况和术后并发症。结果:两组患者在清扫淋巴结、拔除上胸管时间、术后首次下床活动时间、住院时间、术后48 h VAS评分、术后并发症方面,差异无统计学意义(P>0.05)。在手术时间、术中出血量、留置下胸管时间、总引流量、总费用方面,观察组差于对照组(P<0.05)。两组术后随访6~42(23.85±10.12)个月,未有复发、远处转移以及死亡病例发生。结论:磨玻璃结节采用单孔胸腔镜联合肺段切除治疗,安全性和疗效性值得肯定。

Objective:To evaluate the safety and efficacy of uniportal thoracoscopic combined segmentectomy in the treatment of ground-glass nodules.Methods:The clinical data of 79 patients with ground-glass nodules admitted in our hospital from January 2019 to December 2022 were retrospectively selected for study.According to the different surgical methods,48 patients with combined segmentectomy were divided in observation group,31 patients with segmentectomy were divided in control group.The surgical related records and complications were compared.Results:There were no significant differences in number of lymph nodes dissected,upper tube extubation time,postoperative out-of-bed activity,hospitalization days,VAS score and postoperative complications between the two groups(P>0.05).The operation time,lower tube extubation time of the observation group were longer than those of the control group(P<0.05).The intraoperative blood loss,total drainage volume and total hospitalization cost were more than those of the control group(P<0.05).The follow-up time was 6~42(23.85±10.12)months.During the follow-up period,there were no recurrence,distant metastasis or death.Conclusion:For ground-glass nodules,uniportal thoracoscopic combined segmentectomy is safe and feasible.